Stéphane Rohan Laurent, Capnopharm’s VP Sales & Business Development, comments: “Receiving CE certification constitutes a landmark achievement for our new CapnoPen® technology. It also responds to the growing demand from the oncology community for durable, harmonized standards in Intraperitoneal Chemotherapy.”

Capnopharm’s new CapnoPen® is the first PIPAC® nebulizer to obtain CE marking under the new MDR regulation 2017/745. Prof. Marc Reymond, Capnopharm’s CEO, sees here a benefit for the patients and their physicians: “Capnopharm’s new Capnopen® is approved for its effective intended use, namely aerosolizing chemotherapy, DNA, RNA, nanomolecules, viruses, and immunotherapy into body cavities. This is in contrast to other nebulizers on the market which are only approved for aerosolizing aqueous solutions or for irrigating the abdominal cavity: in clinical practice, these nebulizers are used “off-label”. The new Capnopen® is now classified into the appropriate risk category. Its regulatory approval meets the most current MDR standards and is the result of a thorough technical, biological, and clinical evaluation. This evaluation and the resulting approval protect the interests of patients and healthcare practitioners alike”.